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Background: Annexin A5 (anxA5) has been found useful for molecular imaging of apoptosis and other biological
processes.
Methods: Here, we report an optimised two-step synthesis of annexin A5-diethylene triamine pentaacetic acid
(DTPA) (anxA5-DTPA) for positron emission tomography (PET) and single-photon emission computed tomography
(SPECT) imaging with a single purification step. The use of a recombinant annexin A5 (cys-anxA5) with a single thiol
group allowed regionally specific coupling, without affecting the binding domain of cys-anxA5.
Results: The metal complexing capacity of anxA5-DTPA was investigated by labelling with 111In3+ and Eu3+.
Binding of modified anxA5-DTPA to apoptotic cells was tested in competition experiments with a fluorescent
anxA5 derivative (anxA5-FITC) using flow cytometry and compared with that of wildtype anxA5 or non-binding
anxA5-DTPA (M1234-anxA5-DTPA). The binding affinity to apoptotic cells of the anxA5-DTPA conjugate does not
differ from that of wildtype anxA5.
Conclusions: This two-step synthesis of annexin A5-DTPA resulted in biologically active anxA5-DTPA, which can
be labelled with radionuclides for use in SPECT and PET imaging.
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Targeting of externalised phosphatidylserines (PS) using
annexin A5 (anxA5) is relatively unspecific because it will
detect not only apoptotic cells but also, for instance, nec-
rotic cells, ageing cells, hypoxic cardiomyocytes [1],
tumour blood vessels and intravascular thrombi [2].
Nevertheless, imaging using radiolabeled anxA5 can be
used very sensitively and flexibly as a damage marker in a
variety of clinical applications, for instance for monitoring
the response to chemotherapy [3-6], where it is not im-
portant to differentiate apoptotic from necrotic cells.
Moreover, it is possible to visualise purely apoptotic pro-
cesses [7] with high sensitivity.* Correspondence: eyk.schellenberger@charite.de
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in any medium, provided the original work is pModifications are necessary before annexin can be used
as a molecular probe. This is frequently done with amine-
reactive linkers (usually N-hydroxysuccinimide ester),
which randomly react with one or more of the 21 amino
groups localised at lysines in anxA5. Since it has been
shown that this modification reduces the binding activity
of annexin [8], and also, that all four domains present in
anxA5 are necessary for optimal binding affinity [9], it is
important to ensure that the binding properties of anxA5
are not impaired by these reactions.
In the present study, we use the so-called cys-anxA5, a
recombinant variant of anxA5 [10], which enables select-
ive coupling with N-substituted maleimides. Cys-anxA5 is
derived from human anxA5 by replacing a glutamine in
position 2 of the protein with cysteine and a cysteine in
position 315 with serine [10]. This modification provides
the protein with reactive thiol functionality, which is
available for selective coupling chemistry. At pH 7, theOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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times more readily with thiols than with amino groups
(Michael reaction). Since the thiol group is situated in the
concave side of the protein, this modification is unlikely to
affect the convex side of the protein which contains the
PS-binding surface, and therefore, unlikely to affect the af-
finity of the protein for apoptotic cells. To synthesise a
control probe, we used non-binding M1234-cys-anxA5
(inactive, older notation: M1M2M3M4), which has
mutated calcium-binding domains and does not bind
externalised PS on apoptotic cell membranes [11].
Methods
Chemicals
N-(2-aminoethyl) maleimide trifluoroacetate salt,
diethylenetriamine-pentaacetic dianhydride (DTPA-DA),
ethylenediaminetetraacetic acid (EDTA), dithiothreitol
(DTT), anxA5-fluorescein isothiocyanate (FITC) and all
other chemicals including the SDS Gel Preparation Kit were
purchased from Sigma-Aldrich (Steinheim, Germany). So-
dium bicarbonate was purchased from Merck (Darmstadt,
Germany). The bicinchoninic acid (BCA) protein assay was
purchased from Fisher Scientific GmbH (Schwerte,
Germany), cys-anxA5 and M1234-cys-anxA5 from Phar-
maTarget (Maastricht, The Netherlands). BioGel P6 and
protein standards were purchased from Bio-Rad Laborator-
ies GmbH (Munich, Germany) and 111InCl3 solution from
Covidien Deutschland GmbH (Neustadt, Germany).
Step 1: The maleimide-DTPA linker (4)
Finely powdered N-(2-aminoethyl) maleimide trifluoroac
etate salt 2 (29.5 μmol, 7.5 mg) was thoroughly mixed with
finely powdered DTPA-DA 1 (350 μmol, 125 mg) in a 15-
ml Falcon tube. The dry mixture was treated with 2 ml so-
dium bicarbonate solution (0.57 M, half-saturated) at 0°C
(ice/water) with vigorous vortex stirring at 0°C (ice/water)
for a few seconds, followed by stirring for 1 h at 0°C (ice/
water) and 1 h at room temperature. The resulting yellow-
ish solution was analysed by reversed phase high pressure
liquid chromatography (HPLC). Two solvents were used
for elution: Phase A (0.05% trifluoroacetic acid in water)
and Phase B (0.05% trifluoroacetic acid in acetonitrile).
The following gradient was applied, 5–50% B in 15 min.
For electron-spray ionisation mass spectrometry (ESI-MS)
the elution system was: Phase A (5 mM ammonium acet-
ate in water) and Phase B (100% methanol) with a gradient
of 0–30% B in 15 min. The flow rate was 1.0 ml/min on a
Dionex-Ultimate 3000 system using a PDA-100 Photo-
diode Array Detector (Dionex GmbH, Idstein, Germany)
with a Acclaim 120 C18 (250 mm×4.6 mm, 5 μm, 120 Å)
column. Samples were maintained at 25°C and observed at
300 nm. Peak identification was confirmed with ESI-MS
(API 2000 LC/MS/MS System, Applied Biosystems, Foster
City, CA, USA).Step 2: Preparation of cys-anxA5-DTPA (6)
Typical procedure
Potential dimers of cys-anxA5, 5 protein (9.4 mg/ml)
were reduced by incubation with DTT (10 mM final
concentration) for 90 min at 37°C. To remove impurities
and excess DTT, the solution of reduced cys-anxA5, 5
was dialyzed for 24 h at 4°C (25 mM 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES), 140 mM NaCl,
1 mM EDTA, pH 7.4). The resulting protein concentra-
tion was determined by BCA protein assay.
The 60 μl solution of cys-anxA5, 5 (7.2 mg/mL,
0.012 μmol) was added to 10 μl of solution of Step 1, which
corresponds to eight equivalents of maleimide moieties. The
mixture was incubated for 40 min at room temperature and
purified by two rounds of gel filtration using a spin column
with P6 gel (Bio-Rad, 1 ml, 700×g, 4 min). The protein con-
centration of the resulting anxA5-DTPA 6 was determined
by BCA protein assay.
Proteins were analysed by standard sodium dodecyl
sulphate polyacrylamide gel electrophoresis (SDS-PAGE)
and stained with Coomassie blue. The quantification
was done with a G-Box-EF2 gel documentation system
(VWR International GmbH, Darmstadt, Germany).
Quantification of labelling with In3+/111In3+ mixture and
europium
Labelling with In3+/111In3+ mixture
In3+/111In3+ solution, 100 mg InCl3 was dissolved in 1 l
0.02 M HCl. An aliquot of 61.4 μl of this solution was
mixed with 50 μl 111InCl3 solution (0.02 M HCl, 30 MBq,
16.2 ng indium) and 20 μl 0.2 M NH4OAc solution.
Forty microgram of anxA5-DTPA 6 was mixed with
25 μl of the In3+/111In3+ solution, and the mixture was
incubated for 1 h at room temperature. Twenty micro-
litre of a Na2EDTA solution (2.69 mM) was added, and
the mixture was stirred for 10 min at room temperature.
The labelled protein was purified by two rounds of P6
gel filtration as described above. The radioactivity of
both the columns and the filtrate was measured after
each step. The protein concentration of the resulting
complex of 111In3+ with anxA5-DTPA 6 was determined
by BCA protein assay. Cys-anxA5, 5 treated under the
same labelling conditions was used as a control.
Labelling with Eu3+
Twenty microgram of anxA5-DTPA 6 was mixed with
28 μl of EuCl3 solution (0.1 mM), and the solution was
stirred for 1 h at room temperature. Eleven microlitre of a
Na2EDTA solution (2.69 mM) was added, and the mixture
was stirred for 20 min at room temperature. The labelled
protein was purified as described above using a spin col-
umn of P6 gel two times. The concentration of Eu3+ was
estimated by determination of the fluorescence of the euro-
pium chelate formed using an enhancer solution [12] and a
Figure 1 Binding affinity of anxA5-DTPA (6). Competition
experiments demonstrate the inhibition of anxA5-FITC binding to
apoptotic Jurkat T cells by active anxA5-DTPA, wildtype anxA5, and
lack of inhibition by inactive M1234-anxA5-DTPA. The graph shows
normalised median values of fluorescence intensity measured using
flow cytometry (mean of three independent experiments ± SEM for
each concentration).
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ing Eu-anxA5-DTPA complex was determined by BCA
protein assay. The results were verified using unchanged
cys-anxA5, 5 treated under the same labelling conditions.
Cells and competition experiments
Protocols were used as described before [13]. Briefly, Jurkat
T cells were grown according to standard ATCC protocols.
Apoptosis was induced by directly adding camptothecin to
the culture medium (8 μl of 1 mM camptothecin solution
per ml of culture medium) for 6 h. Cells were then washed
twice in binding buffer (1.3 mM CaCl2, 10 mM HEPES,
150 mM NaCl, 5 mM KCl and 1 mM MgCl2, pH 7.4) and
incubated with increasing concentrations of competitors:
active anxA5-DTPA 6, inactive M1234-anxA5-DTPA and
wildtype anxA5. Camptothecin-treated cells resuspended
in 500 μl binding buffer (50,000 in experiments 1 and 3
and 20,000 for experiment 2) were used for each sample.
After adding anxA5-FITC (a fluorescent anxA5 derivative),
its binding to apoptotic cells was established from the me-
dian values of FITC fluorescence intensity in the form of
the highest peaks measured by flow cytometry as
described. The ability to replace anxA5-FITC on apoptotic
Jurkat T cells by active anxA5-DTPA, wildtype anxA5 or in-
active M1234-anxA5-DTPA was analysed by flow cytome-
try (FACS Calibur cytometer, Becton Dickinson GmbH,
Heidelberg, Germany) according to the manufacturer's
instructions. The data were fitted to dose–response curves
with variable slope (Figure 1) to obtain IC50 values as evi-
dence of displacement and the correlation coefficient using
Prism 5 (GraphPad Software, Inc., San Diego, CA, USA).
Molecular modelling
The molecular model of In-anxA5-DTPA was done using
Pymol [14] software and Marvin (ChemAxon Software,
Budapest, Hungary).
Results and discussion
AnxA5-DTPA 6 was synthesised in two-steps as shown in
Figure 2. In the first step, cyclic DTPA anhydride 1 was
reacted with N-(2-aminoethyl) maleimide trifluoroacetate
2 in half-saturated sodium bicarbonate solution at 0°C
(ice/water). The pH of the resulting solution must not ex-
ceed 7.0 in order to prevent premature hydrolysis of the
maleimide functionality. Due to the symmetry of cyclic
DTPA anhydride 1, the di-addition product 3 may form,
which is minimised by using a large excess of cyclic DTPA
anhydride 1 compared to amine 2. The reaction conditions
were optimised for maximising the yield of target linker 4
by modifying a variety of parameters such as concentration
and amounts of reactants. The yield was measured by
HPLC, and an optimal ratio of linker 4 to dimer linker 3
was obtained at 80:20 (mol:mol). Figure 3 shows the HPLC
chromatogram of the reaction products. Peaks wereassigned during the optimisation process supported by
HPLC, ESI-MS and thin layer chromatography including
maleimide detection with Ellman's reagent (5,5′-dithiobis-
(2-nitrobenzoic acid) or DTNB) [15]. The peaks were frac-
tionated and identified with the expected masses by ESI-
MS using negative ion mode [M-H]− as DTPA (m/z 392),
linker 4 (m/z 514) and linker 3 (m/z 636) (Figure 3).
The resulting solution was not purified but directly
reacted with cys-anxA5,5. Before reaction with the pro-
tein, any disulphide bridges must be reduced, and the re-
ducing agent (DTT) removed by dialysis. In a second step,
the linker 4 was reacted with the reduced cys-anxA5, 5,
followed by purification of the protein using double gel fil-
tration over a P6 gel. Different ratios of cys-anxA5, 5 to
linker 4 were tested (2.4-fold, 8-fold and 24-fold molar ex-
cess of linker 4 over cys-anxA5, 5).
The binding capacity of the different anxA5-DTPA coup-
ling products for trivalent metals was tested by labelling with
Eu3+ and 111In3+. For europium labelling, the conjugate 6
was reacted with an excess of europium (III) chloride solu-
tion, and the amount of bound europium was determined
after purification by measuring europium fluorescence by
means of a so-called enhancer solution. The enhancer solu-
tion displaces Eu3+ out of the DTPA complex and ensures
formation of a new, strongly fluorescent Eu3+ complex, from
which the amount of europium can be determined using a
calibration curve. Quantification by means of 111In3+ labelling
was done with an excess of a mixture of cold In3+ and hot
111In3+ in ammonium acetate buffer with subsequent gel fil-
tration over a P6 gel. The radioactivity persisting after two fil-
trations was measured and related to the amount of protein.
Labelling efficiencies for metals are listed in Table 1. A model
of In3+-labelled cys-anxA5-DTPA 6 is shown in Figure 4.
Figure 2 Synthesis of anxA5-DTPA 6. 1) Excess of cyclic DTPA anhydride 1 was reacte d with N-(2-aminoethyl) maleimide trifluoroacetate 2 in
half-saturated sodium bicabonate solution. 2) Reaction product 4 was regiospecifically coupled with the thiol group of cys-anxA5, 5. Due to
complete hydrolysis of excess anhydride 1 during a 2-h reaction, the reaction solution from the first step could be used directly without
purification. The conjugate 6 was purified by gel filtration.
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jugates for subsequent experiments were synthesised with
eightfold excess of linker 4 in step 1. For comparison, this
was done with both the binding (active) form, cys-anxA5,
5 and the non-binding (inactive) form, M1234-cys-anxA5.
The conjugates, anxA5-DTPA 6 and M1234-anxA5-
DTPA, were examined by standard SDS-PAGE gel elec-
trophoresis and Coomassie staining (Figure 5). The yield
of anxA5-DTPA 6 and M1234-anxA5-DTPA was about
60% and 49%, respectively (Figure 5b).
Binding of active anxA5-DTPA (6) construct to Jurkat T
cells with induced apoptosis
The binding capabilities of cys-anxA5 constructs were
analysed via competition measurements between active
anxA5-DTPA 6 and anxA5-FITC, inactive M123-anxA5-
DTPA and anxA5-FITC as well as wildtype anxA5 andanxA5-FITC for binding to apoptotic Jurkat T cells. The
dose–response graph summarising three independent
experiments (Figure 1) shows that active anxA5-DTPA 6
can effectively inhibit anxA5-FITC, with an IC50 of 6.2
nM (95% confidence interval 4.8 to 8.1 nM, R2 = 0.97),
whereas wildtype anxA5 displaces anxA5-FITC with an
IC50 of 5.3 nM (95% confidence interval 3.3 to 8.7 nM,
R2 = 0.95). These results indicate that active anxA5-DTPA
6 has a similar affinity as wildtype anxA5. The inactive
M1234-anxA5-DTPA was not able to inhibit anxA5-FITC
binding to apoptotic Jurkat cells, as expected.
The optimised method for the direct synthesis of
maleimide-DTPA linker 4 from cyclic DTPA anhydride 1
and N-(2-aminoethyl) maleimide trifluoroacetate 2 pre-
sented here enables single-step synthesis using inexpen-
sive reactants. The method is straightforward to perform,
and the resulting linker 4 can be purified by HPLC if
Figure 3 HPLC chromatogram of the reaction between
N-(2-aminoethyl) maleimide trifluoroacetate (2) and cyclic DTPA
anhydride (1). The peaks represent unreacted, hydrolysed DTPA
(peak a), linker 4 (peak b) and byproduct 3 (peak c). Because of the
presence of two UV-absorbing maleimide groups, the concentration
of byproduct 3 is given by half of the peak integral in relation to
peak b. The resulting ratio of product 4 to byproduct 3 is
approximately 80:20.
Figure 4 Model of In-anxA5-DTPA. The blue spheres are Ca2+ in
the binding pockets at the PS-binding side of anxA5. DTPA is linked
to the opposite side of the PS-binding domain of the protein. In3+ is
represented as a brown sphere. (Crystal structure modified from
Huber et al. [16]).
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fast hydrolysis of the anhydride prevents side reactions with
amines of cys-anxA5, 5, and the resulting DTPA excess is
removed by gel filtration after reaction 2 (Figure 2). Proce-
dures for linker synthesis 4 described in the literature com-
prise eight [17] or five synthesis steps [18] and involve use
of complex protecting group chemistry and purification
steps. Subsequent reaction of the linker 4 with cys-anxA5,
5 resulted later in labelling efficiencies of 46–59% (labelling
with In3+/111In3+ mixture), depending on the reaction con-
ditions (Table 1). Arano et al. coupled linker 4 with an IgG
antibody and found a good stability of the 111In3+-labelled
conjugate during incubation for 120 h at 37°C in human
serum, with about 10% loss of corrected radioactivity [17].
To preclude reactions with the amino groups of cys-
anxA5, 5, linker 4 was added in excess, and the reaction
time was limited to 40 min. Overall, two synthesis steps and
one purification step lead to the desired conjugate 6. Based
on the HPLC chromatogram, the linker dimer 3 accounts
for only 20%, and there is negligible formation of protein-Table 1 Labelling results of conjugates with Eu3+ and 111
In3+
Incubation method 111In3+ labelling in % Eu3+ labelling in %
2.4-fold excess of linker 4 46.2 36.7
8-fold excess of linker 4 53.1 36.2
24-fold excess of linker 4 58.6 41.7
for comparison:
cys-anxA5 5 0.0 0.0
In case of europium the yield was determined by measuring the fluorescence,
in case of 111In3+ by radioactivity measurement. The numbers are percentages
of labelled protein.linker dimer from linker dimer 3 and cys-anxA5, 5 accord-
ing to SDS gel electrophoresis (Figure 5). One question is
whether two cys-anxA5, 5 would react with one linker
dimer 3 at all or whether this is precluded for steric reasons.
The coupling product that might arise in this way (linker
dimer 3 with one or two cys-anxA5, 5) would have a lower
affinity for the metals to be complexed [19] than anxA5-
DTPA 6 due to the presence of two amides in the chelator.
The yield of the DTPA coupling reaction was estimated by
quantification of the protein gel electrophoresis, and divid-
ing the band with DTPA derivatives by the sum of all bands
(Figure 5b). Our coupling results are similar to yields using
Cy5.5-maleimide (GE Healthcare, Solingen, Germany), andFigure 5 Coomassie stained SDS-PAGE of anxA5-DTPA (6).
(A) The lanes show cys-anxA5, 5 (a) and M1234-anxA5 (b) in
comparison to M1234-anxA5-DTPA (c) and anxA5-DTPA 6 (d) (both
synthesised with eightfold excess of linker 4 in step 1). Lanes c and d
show M1234-anxA5-DTPA and anxA5-DTPA 6 plus unreacted M1234-
cys-anxA5 and cys-anxA5, 5. Note: No or minimal protein-linker dimers
(from linker dimer 3 and cys-anxA5, 5) are visible. (B) Gel quantification
revealed 49% yield for M1234-anxA5-DTPA (a) and 60% for anxA5-
DTPA 6 (b) by dividing band 2 (DTPA derivatives) by the sum of all
three bands. cys-anxA5 dimers resulting from thiol oxidation (70 kDa)
are also visible (band 3).
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coupling was never achieved, possibly due to steric hin-
drance of the cysteine of cys-anxA5.
Using the conjugate 6 prepared with an eightfold excess
of linker 4, we performed competition experiments (FACS)
with anxA5-FITC and apoptotic Jurkat T cells. For these
experiments, a conjugate was prepared from non-binding
M1234-cys-anxA5 under identical reaction conditions and
compared with binding anxA5-DTPA 6 in terms of their
capacity to displace anxA5-FITC. The binding capacity we
measured is comparable to that of wildtype anxA5, demon-
strating the advantages of second generation cys-anxA5, 5
over first generation annexin A5 [8]. The specific reaction
of maleimide with the single thiol group ensures that full
binding activity is retained, because the thiol group is
located in the concave side of the protein whereas the four
PS binding domains of anxA5 are in the convex side.
To verify the reaction of cys-anxA5, 5 with linker 4, we
determined its metal chelating capacity, by labelling experi-
ments with 111In3+ and Eu3+ as an additional non-
radioactive method. The assumption is made that due to
the high stability of such complexes, the metal binding cap-
acity is close to the amount of DTPA coupled to cys-anxA5,
5 [17]. The protein samples labelled with an excess of metal
were treated with about tenfold excess of EDTA to 111In3+
or Eu3+ and then gel filtered to remove excess metal and
preclude nonspecific binding of the metals to the protein.
The quantitative results of labelling with 111In3+ showed a
better correspondence with the results of the protein gel
(Figure 5b). In the case of europium labelling, Eu3+ was
subsequently displaced from the DTPA complex by
addition of an enhancer solution [12] and reacted to form a
new, strongly fluorescent complex. The concentration of
europium was determined using a calibration curve. This
method performs very well due to the high sensitivity of
fluorescence measurement but is somewhat dependent on
pH [12]. Additionally the complex of Eu3+ with DTPA is
more than six orders of magnitude weaker in comparison
to In3+ [20], which might explain the lower values com-
pared with 111In3+-labelling. The resulting conjugate 6 can
be labelled with 99mTc(CO)3
+ [10], or 111In3+ for SPECT
applications or with 68Ga3+ for PET experiments [21].
Conclusions
In summary we demonstrated an efficient method for
thiol-mediated protein labelling with DTPA, which should
be applicable to other proteins including antibodies. The
anxA5-DTPA 6 presented here is available as a new pre-
cursor for apoptosis imaging for in vitro and in vivo
experiments that retains its PS-binding capacity due to
the chemical specificity of the coupling reaction.
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